Wellington S, Nag PP, Michalska K, Johnston SE, et al. A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol. 2017;13(9):943-950.
Bekendam RH, Bendapudi PK, Lin L, Nag PP, et al. A substrate-driven allosteric switch that enhances PDI catalytic activity. Nat Commun. 2016;7:12579.
Grant, SS, Kawate, T, Nag, PP et al. Identification of Novel Inhibitors of Nonreplicating Mycobacterium tuberculosis Using a Carbon Starvation Model. ACS Chem. Biol. 2013; 8, 2224-2234.
Partha Nag, Ph.D.
Partha P. Nag is a senior scientist in the Chemical Biology and Therapeutics Science (CBTS) at the Broad Institute of MIT and Harvard. His current research focuses on the rational design and development of novel antibiotics and anti-infectives for clinical development. Two of the more advanced therapeutic discovery and development projects involve developing small molecule drugs with novel modes of action against Mycobacterium tuberculosis and Plasmodium falciparum. The lead series, identified from the Broad Institute’s Diversity Oriented Synthesis Library, are structurally distinct from current approved drugs and target unique proteins and biological pathways. As a senior scientist, Nag works closely with the Bill & Melinda Gates Foundation, TB Drug Accelerator, TB Alliance, Medicines for Malaria Venture, Eisai (pharmaceutical partner), and other academic collaborators to build a large project team to advance the key goals of the project. Nag has significant expertise in chemical biology, drug discovery (hit-to-lead and lead optimization), organic and medicinal chemistry, library design, target identification, and structural biology.
Nag pursued his doctoral studies under the mentorship of Professor David R. Williams at Indiana University, Bloomington. The primary focus of his doctoral work was the total synthesis of Daphniphyllum alkaloids daphnicyclidin C. In 2009, he joined the Therapeutics Platform at the Broad Institute as a postdoctoral associate (under the supervision of Michael Foley and Stuart L. Schreiber) and worked on small-molecule chemical probe development projects as part of the NIH’s Molecular Libraries Program (MLP). These works spanned across infectious disease, cancer, CNS, and cardiovascular therapeutic areas, providing early-stage lead chemical compounds to validate new drug targets for the scientific communities.
Contact Partha P. Nag via email at email@example.com.